| Project/Area Number |
16K20015
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
Kuga Daisuke 九州大学, 医学研究院, 助教 (40759932)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | glioblastoma / liquid biopsy / 膠芽腫 / Glioblastom / bevacizumab / バイオマーカー |
|---|
| Outline of Final Research Achievements |
The purpose of this study is to predict the clinical course, efficacy of treatment in the patients with Bevacizumab treated glioblastoma analyzing the cell free DNA from tumor cell in the patients' blood. However, we were not able to detect any mutation of target gene in the patients' blood, indicating cell free DNA was not released into the blood. Then we used the patients' CSF as alternative candidate. We were able to some genes which originated from tumor cell in the patients' CSF. These results imply that CSF may be a good candidate for liquid biopsy in the patients with GBM.
|
